- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Chugai acquires Renalys, enhancing its kidney disease portfolio | 2 | Pharmaceutical Technology | ||
| 24.10. | Chugai buys a kidney biotech; ICER targets rising launch prices | 4 | BioPharma Dive | ||
| 24.10. | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | 29 | FiercePharma | ||
| 24.10. | Chugai buys 'Asia lag' firm Renalys for $98m upfront | 3 | pharmaphorum | ||
| 24.10. | Chugai Pharmaceutical 9-month Net Income Rises | 248 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 23.10. | Roche axes 4 Chugai solid tumor assets in early-phase clearout | 10 | FierceBiotech | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 17.10. | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | 12 | FierceBiotech | ||
| 17.10. | Rani Therapeutics surges on Chugai licensing deal, private placement | 31 | Seeking Alpha | ||
| 17.10. | Rani Therapeutics: Aktie schießt nach potenziellem Milliarden-Deal mit Chugai in die Höhe | 37 | Investing.com Deutsch | ||
| 17.10. | Rani Therapeutics stock soars after inking $1 billion potential deal with Chugai | 11 | Investing.com | ||
| 17.10. | Rani Therapeutics signs $1 billion potential deal with Chugai for oral biologics | 4 | Investing.com | ||
| 17.10. | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 368 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| 27.08. | Chugai spikes after Eli Lilly trial win for obesity pill | 22 | Seeking Alpha | ||
| 08.08. | Chugai stock drops the most since 1977 on disappointing obesity drug data | 32 | Japan Times | ||
| 24.07. | Chugai Pharmaceutical reports Q2 results | 9 | Seeking Alpha | ||
| 08.07. | Chugai and Gero link on antibody drugs for age-related conditions | 5 | Pharmaceutical Technology | ||
| 19.06. | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | 707 | JCN Newswire | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen | |
| 19.05. | Rani Therapeutics erforscht orale Verabreichung von Chugai-Medikamenten | 10 | Investing.com Deutsch | ||
| 19.05. | Rani Therapeutics explores oral delivery of Chugai's drugs | 4 | Investing.com | ||
| 19.05. | Rani Therapeutics Announces Research Agreement with Chugai | 657 | GlobeNewswire (Europe) | - Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 6,370 | +1,76 % | Why Trulieve Cannabis Stock Sank by 4% Today | ||
| WEST PHARMACEUTICAL SERVICES | 247,10 | +0,53 % | Evercore ISI bestätigt "Outperform"-Rating für West Pharmaceutical | ||
| SHIONOGI | 14,700 | +1,38 % | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| KALA BIO | 0,649 | -6,62 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
| CHARLOTTES WEB | 0,101 | -17,89 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Year-Over-Year Growth For Q2 2025 | Second Consecutive Quarter of Year-over-Year Revenue Growth Supported by New Product Innovations and Omnichannel Expansion
LOUISVILLE, Colo., Aug. 13, 2025 ... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,468 | +0,43 % | Beximco Pharma seeks extension to publish FY 2025 results | ||
| LUYE PHARMA | 0,354 | +3,51 % | LUYE PHARMA (02186): INTERIM REPORT 2025 | ||
| PERCHERON THERAPEUTICS | 0,004 | -11,11 % | Edison Group: Edison Issues Report on Percheron Therapeutics (PER) | London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron Therapeutics has reported final results from the Phase I dose escalation... ► Artikel lesen | |
| AYURCANN | 0,015 | +26,09 % | Ayurcann Holdings Corp: Ayurcann's fiscal 2025 revenue at $55.44-million | ||
| MIRUM PHARMACEUTICALS | 62,00 | -1,59 % | 8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know | ||
| AVANT BRANDS | 0,358 | 0,00 % | Avant Brands Inc.: Avant Brands Announces Results for Q3 2025 | KELOWNA, BC / ACCESS Newswire / October 15, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BUP) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products... ► Artikel lesen | |
| KALBE FARMA | 0,057 | -6,61 % | Kalbe Farma profit rises 10.63%, shares react positively: The shares of this Indeks52 constituent climb 3.25% ... | ||
| EVEREST MEDICINES | 5,450 | +2,83 % | Everest Medicines Limited: Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders | HONG KONG, Oct 30, 2025 - (ACN Newswire) - Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. ('Visara'), a subsidiary of NovaBridge Biosciences... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 28,400 | -1,39 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
| ALLIANCE PHARMA | 0,670 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +8,79 % bei einem Aktienkurs von 19,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.